$DBVT News

DBV Technologies Starts Infant Study of Peanut Allergy Patch

Guggenheim Reiterates Buy on DBV Technologies, Maintains $51 Price Target

European Equities Traded in the US as American Depositary Receipts Flat in Friday Trading; Gain 1.3% for Week

Citizens Maintains Market Outperform on DBV Technologies, Raises Price Target to $55

DBV Technologies Reports First Quarter 2026 Financial Results

DBV Technologies Q1 EPS $(0.11) Beats $(0.12) Estimate, Sales $900.000K Miss $1.268M Estimate

European Equities Traded in the US as American Depositary Receipts Track Lower in Monday Trading

Is COMPASS Pathways (CMPS) Outperforming Other Medical Stocks This Year?

Is It Too Late To Consider DBV Technologies (ENXTPA:DBV) After Its 1-Year 173% Surge?

DBV Technologies: A Cohort-Driven Model That Could Support Blockbuster VIASKIN Revenue

DBV Technologies (DBVT) Upgraded to Buy: What Does It Mean for the Stock?

Wall Street Analysts Predict a 79.04% Upside in DBV Technologies (DBVT): Here's What You Should Know

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of March 31, 2026

Scancell CFO to step down as cancer immunotherapy developer names interim replacement

DBV Technologies: A Tough Nut To Crack In A Shrinking Market

DBV Technologies Sets Stage For 'Swift' Success As Breakthrough Peanut Patch Nears FDA Submission

Citizens Maintains Market Outperform on DBV Technologies, Raises Price Target to $47

Guggenheim Reiterates Buy on DBV Technologies, Maintains $51 Price Target

DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document

DBV Technologies Reports Full Year 2025 Financial Results and Business Update